Mark L Warren (Mark Warren)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 11

Top Topics

Recombinant Human

Community Dwelling

Top Venues

Diabetes, obesity & metabolism

Journal of the Endocrine Society

This page only lists publications with an associated author ORCID identifier.

Publications

Elena A Christofides, Orlando Puente, Paul Norwood, Douglas Denham, Hiralal Maheshwari, Michael Lillestol, Terence Hart, Samer Nakhle, Anurekha Chadha, David Fitz-Patrick, Danny H Sugimoto, Joseph Soufer, Douglas Young, Mark L Warren, David Huffman, John Reed, Harold Bays, Samir Arora, Barbara Rizzardi, Raymond Tidman, Marc Rendell, Kimball A Johnson
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study. Diabetes, obesity & metabolism 26 (6) (2024)
Elena A Christofides, Orlando Puente, Paul Norwood, Douglas Denham, Hiralal Maheshwari, Michael Lillestol, Terence Hart, Samer Nakhle, Anurekha Chadha, David Fitz-Patrick, Danny H Sugimoto, Joseph Soufer, Douglas Young, Mark L Warren, David Huffman, John Reed, Harold Bays, Samir Arora, Barbara Rizzardi, Raymond Tidman, Marc Rendell, Kimball A Johnson
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study. Diabetes, obesity & metabolism (2024)
Elena A Christofides, Orlando Puente, Paul Norwood, Douglas Denham, Hiralal Maheshwari, Michael Lillestol, Terence Hart, Samer Nakhle, Anurekha Chadha, David Fitz-Patrick, Danny H Sugimoto, Joseph Soufer, Douglas Young, Mark L Warren, David Huffman, John Reed, Harold Bays, Samir Arora, Barbara Rizzardi, Raymond Tidman, Marc Rendell, Kimball A Johnson
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study. Diabetes, obesity & metabolism 26 (6) (2024)
Nelson B Watts, John P Bilezikian, Henry G Bone, Bart Lyman Clarke, Douglas Denham, Michael A Levine, Michael Mannstadt, Munro Peacock, Jeffrey H Rothman, Tamara J Vokes, Mark L Warren, Shaoming Yin, Nicole Sherry, Dolores M Shoback
Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism. Journal of the Endocrine Society 7 (5) (2023)
Nelson B Watts, John P Bilezikian, Henry G Bone, Bart Lyman Clarke, Douglas Denham, Michael A Levine, Michael Mannstadt, Munro Peacock, Jeffrey H Rothman, Tamara J Vokes, Mark L Warren, Shaoming Yin, Nicole Sherry, Dolores M Shoback
Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism. Journal of the Endocrine Society 7 (5) (2023)
Nelson B Watts, John P Bilezikian, Henry G Bone, Bart Lyman Clarke, Douglas Denham, Michael A Levine, Michael Mannstadt, Munro Peacock, Jeffrey H Rothman, Tamara J Vokes, Mark L Warren, Shaoming Yin, Nicole Sherry, Dolores M Shoback
Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism. Journal of the Endocrine Society 7 (5) (2023)
Nelson B Watts, John P Bilezikian, Henry G Bone, Bart Lyman Clarke, Douglas Denham, Michael A Levine, Michael Mannstadt, Munro Peacock, Jeffrey H Rothman, Tamara J Vokes, Mark L Warren, Shaoming Yin, Nicole Sherry, Dolores M Shoback
Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism. Journal of the Endocrine Society 7 (5) (2023)
Mark L Warren, Bruce Bode, Jang I Cho, Rong Liu, Janet Tobian, Thomas Hardy, Farai Chigutsa, Moshe Phillip, Barry Horowitz, Debra Ignaut
Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2. Diabetes, obesity & metabolism 23 (7) (2021)
Esteban Jódar, Marie Michelsen, William Polonsky, Rosangela Réa, Anna Sandberg, Tina Vilsbøll, Mark L Warren, Signe Harring, Uwe Ziegler, Stephen C Bain
Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6). Diabetes, obesity & metabolism 22 (8) (2020)
Mark L Warren, Louis Chaykin, David Trachtenbarg, Gurudutt Nayak, Nelun Wijayasinghe, Bertrand Cariou
Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials. Diabetes, obesity & metabolism 20 (9) (2018)
Bo Ahrén, Stephen L Atkin, Guillaume Charpentier, Mark L Warren, John P H Wilding, Sune Birch, Anders Gaarsdal Holst, Lawrence Alan Leiter
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes, obesity & metabolism 20 (9) (2018)